Allos AI

Allos AI is an Oxford-based drug reformulation company applying causal AI to one of the most persistently underfunded problems in pharmaceutical development: improving medicines that already exist. While the majority of AI investment in drug discovery has focused on finding new molecules, Allos targets the formulation gap — the reality that millions of patients with chronic conditions rely on drugs that work clinically but are difficult to tolerate, adhere to, or sustain over time due to how they are formulated and delivered.

The challenge is structural. Improving an approved drug’s formulation often requires restarting significant portions of the development and clinical pathway, creating cost, regulatory complexity, and commercial risk that has historically discouraged manufacturers from reinvesting in existing medicines. As a result, patients remain on suboptimal formulations for years, and a growing specialty generics market — projected to reach $275 billion by 2032 — remains largely underserved.

Allos AI’s platform applies causal AI to model how formulation, dosing, delivery method, and patient biology interact to drive clinical outcomes. By grounding its models in real-world evidence from health records, the platform accounts for patient and disease heterogeneity upfront — enabling smaller, faster, and more interpretable clinical studies. Its ‘glass-box’ approach means the reasoning behind every output is interpretable and auditable, a critical feature for pharmaceutical partners and regulatory submissions. The company’s initial focus is on hard-to-genericise small-molecule medicines in chronic disease.

Allos AI was founded by a team combining Oxford-trained researchers and industry veterans in complex generics. CEO and co-founder Aditya Iyer holds a DPhil in Quantum Information Theory from the University of Oxford. The company raised £4 million in seed funding in January 2026, led by Oxford Science Enterprises, with participation from Habico Invest — the family office of Danish pharmaceutical group Orifarm — and Berkeley SKYDECK.